Tolerability of imidazole salycilate in aspirin-sensitive patients.

Abstract

Over the last few years, many studies have been carried out in order to individualize which nonsteroidal anti-inflammatory drug (NSAID) can be tolerated in aspirin sensitivity. Imidazole salicylate (IS) is a new NSAID that inhibits Tromboxane A2 synthesis, without interferring with cyclo-oxygenase pathway, whose inhibition was demonstrated to cause asthma and/or urticaria/angioedema in aspirin-sensitive patients. We enrolled 67 subjects with documented intolerance to aspirin, pyrazolones or NSAIDs, clinically manifested as urticaria/angioedema (68%), asthma, and/or rhinitis (32%). A challenge with IS was carried out in every patient in single-blind fashion, reaching a cumulative dosage of 1000 mg in the fourth session. No appearance of urticaria or bronchospastic reactions was registered in any subject, confirming the safe use of IS in aspirin-sensitive patients.

• Authors: G E Senna, G Andri, A R Dama, P Mezzelani, L Andri
• Journal: Allergy proceedings : the official journal of regional and state allergy societies (Allergy Proc) 1995 Sep-Oct Vol. 16 Issue 5 Pg. 251-4 ISSN: 1046-9354 [Print] United States
• PMID: 8566739 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Cyclooxygenase Inhibitors
• Enzyme Inhibitors
• Imidazoles
• imidazole
• Aspirin

Topics

• Adolescent
• Adult
• Aspirin (adverse effects)
• Asthma (chemically induced, drug therapy)
• Bronchial Provocation Tests
• Child
• Cyclooxygenase Inhibitors (adverse effects)
• Drug Hypersensitivity (drug therapy, etiology)
• Enzyme Inhibitors (therapeutic use)
• Female
• Humans
• Imidazoles (therapeutic use)
• Male
• Middle Aged
• Single-Blind Method
• Urticaria (chemically induced, drug therapy)